An Exploratory, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of BYM338 on Muscle in Patients Requiring Prolonged Mechanical Ventilation
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2017
Price : $35 *
At a glance
- Drugs Bimagrumab (Primary)
- Indications Muscular atrophy
- Focus Pharmacodynamics
- Sponsors Novartis
- 23 Mar 2017 Status changed from recruiting to Discontinued as reported by European Clinical Trials Database record.
- 19 Jun 2014 Planned End Date changed from 1 Nov 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 08 Apr 2014 New source identified and integrated European Clinical Trials Database; EudraCT2013-002201-66